



Aortic Aneurysms: Vascular Remodeling and Repair 2.0

Guest Editor:

Dr. Elena Kaschina

Center for Cardiovascular
Research and Institute of
Pharmacology, Charité –
Universitätsmedizin Berlin,
Hessische Strasse 3-4, D-10115
Berlin, Germany

Deadline for manuscript
submissions:

31 January 2024

Message from the Guest Editor

Dear Colleagues,

Aortic aneurysm is a multifactorial disease that is characterized by vascular remodeling due to degradation of the extracellular matrix and reduced vascular repair. It is commonly associated with atherosclerosis, hypertension, and thrombotic disorders. Present treatment options are restricted to surgical interventions such as endovascular stents or open surgical procedures that are not appropriate for all patients. Thus, there is a need for specific and effective new treatments that prevent aneurysmal growth, reduce the risk of rupture, and prevent aneurysmal extension after surgical repair. New discoveries in the field of translational biology, cell therapy, and regenerative medicine, together with new approaches to experimental design and target drug release, should accelerate the development of new therapies.

This Special Issue invites both original manuscripts that describe novel findings and cutting-edge review articles that illustrate recent advances in molecular and cell biology, pathophysiology, biomarkers, novel non-surgical medications, and targeted drug delivery for aortic aneurysm.

Dr. Elena Kaschina

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[@Biomed_MDPI](https://twitter.com/Biomed_MDPI)